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Abstract
Background: Although many apheresis centers offer extracorporeal photopheresis
(ECP), little is known about current treatment practices.
Methods: An electronic survey was distributed to assess ECP practice
internationally.
Results: Of 251 responses, 137 met criteria for analysis. Most respondents were
from North America (80%). Nurses perform ECP at most centers (84%) and the
majority of centers treat adults only (52%). Most centers treat fewer than 50 patients/
year (83%) and perform fewer than 300 procedures/year (70%). Closed system
devices (XTS and/or Cellex) are used to perform ECP at most centers (96%). The
most common indications for ECP are acute/chronic skin graft versus host disease
(89%) and cutaneous T-cell lymphoma (63%). The typical wait time for ECP treat-
ment is less than 2 weeks (91%). Most centers do not routinely perform quality
control assessment of the collected product (66%). There are device-specific differen-
ces in treatment parameters. For example, XTS users more frequently have a
minimum weight limit (P5 0.003) and use laboratory parameters to determine eligi-
bility for treatment (P5 0.03). Regardless of device used, the majority of centers
assess the clinical status of the patient before each procedure. Greater than 50% of
respondents would defer treatment for hemodynamic instability due to active sepsis
or heart failure, positive blood culture in the past 24 h or current fever.
Conclusion: This survey based study describes current ECP practices. Further
research to provide evidence for optimal standardization of patient qualifications, pro-
cedure parameters and product quality assessment is recommended.
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1 | INTRODUCTION
Although many apheresis centers offer extracorporeal photo-
pheresis (ECP), little is known about current practice pat-
terns. In this study, we used a survey tool to examine the
scope of current ECP practices among a large cohort of
respondents who represent apheresis services worldwide.
The objective of this study was to describe current practices
and identify areas that may warrant further research.
Extracorporeal photopheresis (ECP) is an antitumor/
immunomodulatory apheresis treatment in which leukocytes
from the patient’s peripheral blood are separated by centrifu-
gation and treated with 8-methoxypsoralen (8-MOP). The
latter is a naturally occurring substance that is activated fol-
lowing exposure to ultraviolet (UV) light resulting in DNA
intercalation and ultimately apoptosis of treated cells.1 Fol-
lowing extracorporeal photoactivation, treated white blood
cells (WBCs) are reinfused into the patient. Exactly how
reinfusion of photoactivated cells results in anti-tumor and
immunosuppressive effects remains incompletely under-
stood.2 In addition to apoptosis, ECP has been shown to pro-
mote development of dendritic cells which, depending on the
amount of UV exposure and interactions with other compo-
nents of blood within the device, become either immature or
mature dendritic cells which promote an anti-inflammatory
state or an anti-tumor effect, respectively. After several
months of ECP treatments, an increase in circulating regula-
tory T-cells and tolerogenic dendritic cells has been seen that
persists following discontinuation of ECP.3
The Therakos XTS (XTS) was the first closed-system
device approved for ECP by the Food and Drug Administra-
tion in 1988. This approval was granted based on a multicen-
ter clinical trial which showed a positive response rate in
patients with advanced refractory cutaneous T-Cell lym-
phoma (CTCL) treated with ECP.4 Approval in Europe and
elsewhere around the world followed shortly thereafter. The
Therakos Cellex (Cellex), a second commercially available
closed system device for ECP from the same manufacturer,
was approved in Europe in April 2008, Canada in January
2009, and the United States in March 2009. The XTS is a dis-
continuous flow instrument while the Cellex is a continuous
flow instrument. Advantages of the Cellex include smaller
ECV and shorter procedure times.5,6 The procedure manuals
for both instruments do not specify a lower limit for patient
weight, hematocrit or other laboratory parameters. Users must
determine patient total blood volume and safe ECV based on
patient hematocrit using tables provided in the procedure
manual. There are no recommended quality control proce-
dures to assess the collected product for either device.
At the time of our study, the most recent evidence based
guidelines for ECP were those published by the American
Society for Apheresis (ASFA) in 2013.7 In these guidelines,
the only category I indication for ECP (first line therapy,
either as primary standalone treatment or in conjunction with
other modes of treatment) is erythrodermic CTCL. Category
II indications (second line therapy, either as standalone treat-
ment or in conjunction with other modes of treatment)
include cellular or recurrent rejection or rejection prophylaxis
in cardiac transplantation, acute/chronic skin graft versus
host disease (GVHD) and lung allograft rejection/bronchioli-
tis obliterans syndrome. Category III indications (disorders
for which the role of ECP is unestablished) include non-
erythrodermic CTCL, acute/chronic non-skin GVHD,
Crohn’s disease, nephrogenic systemic fibrosis, pemphigus
vulgaris, psoriasis and scleroderma.
2 | METHODS
An electronic survey containing 43 questions was prepared
by the ASFA ECP subcommittee.
2.1 | Center demographics
Initial survey questions obtained the name and location of the
responding center, the role of the person completing the sur-
vey, and whether or not ECP is performed at that institution.
For those centers performing ECP, subsequent questions
included job classification of staff performing ECP, age
range of patients treated with ECP, number of both patients
and ECP procedures performed per year and devices used to
perform ECP,
2.2 | General ECP practice patterns
Subsequent questions focused on ECP practice patterns
including indications for ECP, typical wait time for treat-
ment, barriers to receiving ECP treatment, types of venous
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access used, and quality control assessment of the product
collected for UV photoactivation.
2.3 | Device-specific practices
General practice questions were followed by questions about
device-specific ECP practices including patient weight limi-
tations, volume prime practices, laboratory or clinical find-
ings that would prevent ECP from being performed and
anticoagulant(s) used.
2.4 | Survey development, distribution and analysis
The survey was developed by members of the ASFA ECP
subcommittee. Prior to general circulation, the survey was
“beta-tested” by apheresis staff (physicians and nurses) not
on the ECP committee to assess clarity of questions and time
required to complete the survey.
An internet-based tool (Survey Monkey, Palo Alto, CA,
www.surveymonkey.com) was utilized to administer the sur-
vey which was sent via email to over 5000 possible partici-
pants in the United States and abroad using the ASFA
electronic distribution lists. Given the breadth of the ASFA
membership, it is likely that more than one person received
the survey at each institution but only one response per institu-
tion was retained for analysis. When multiple responses were
received, the one selected for data analysis was chosen based
on the respondent’s role according to the hierarchy of Medical
Director, Supervisor, Nurse, Physician and Medical Technolo-
gist. Responses were collected over a one-month time period
(April 2015) and analyzed using descriptive statistics. Pediat-
ric patients were defined as those under 18 years of age.
Percentages for individual survey items were calculated
based on the number of responses received for each question.
Categorical data were analyzed using Fisher’s exact test to
calculate a two-tailed P value. For continuous data, an
unpaired t test was performed to compare means. A P values
of less than 0.05 was considered statistically significant. All
analyses were done with web-based software (GraphPad
QuickCalcs, La Jolla, CA, www.graphpad.com).
3 | RESULTS
3.1 | Center demographics
The study yielded 251 responses, of which 56 were excluded
as duplicates, seven were excluded because they contained
insufficient information to determine whether or not they
were duplicates, and 51 because they were from centers that
do not perform ECP (Figure 1). The remaining 137 evaluable
responses came primarily from centers in North America and
Europe (Figure 2). Center demographic information is shown
in Table 1.
3.2 | General ECP practice patterns
ECP is most frequently performed for acute/chronic GVHD
with skin involvement followed by CTCL and acute/chronic
GVHD with non-skin involvement. A minority of centers are
performing ECP for uncategorized indications per the 2013
ASFA guidelines.7 Center responses for indications for ECP
and 2013 ASFA categorization are shown in Table 2. Data on
typical wait time for treatment, barriers to receiving ECP treat-
ment, types of venous access used, performance of quality con-
trol and quality control parameters are shown in Table 3.
3.3 | Device-specific practices
Centers using the Cellex and/or XTS devices provided addi-
tional device specific practice information shown in Table 4.
Although the majority respondents indicated that their center
has a minimum weight limit to enable treatment on the XTS
device, most do not require a minimum weight for treatment
on the Cellex device (P5 0.003). Among centers that pro-
vided their minimum weight requirements, the cut-offs varied
widely both within and between the different devices used
FIGURE 1 Survey total number of responses, exclusions
and final number of responses analyzed
FIGURE 2 Survey responses (%) by geographic location
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(Figure 3). The average minimum weight for treatment on
the Cellex was 27 kg compared to an average minimum
weight of 36 kg for treatment on the XTS (P5 0.0095).
Although the majority of responding centers indicated
that the decision to perform ECP is influenced by patient lab-
oratory parameters, regardless of the device used, a higher
percentage of XTS users reported using laboratory test
results to determine eligibility for ECP when compared to
Cellex users (P5 0.03). Laboratory values commonly
assessed to determine eligibility for ECP include hematocrit,
platelet count and WBC count. There is little agreement on
the cut-off used for these assays (Figure 4).
4 | DISCUSSION
This report represents the first published survey to specifi-
cally assess ECP practice patterns by apheresis providers.
We believe that it contains important information to guide
future research. We found that the majority of centers per-
forming ECP treat small numbers of patients. This observa-
tion is significant because it represents a model which in
general lends to greater variation, lower adherence to proto-
cols, and increased complications and cost.8–10 However, we
also observed that center staffing, number of devices and dis-
tance to the center are barriers to care reported by up to a
quarter of participating ECP centers. This suggests that
access to ECP is problem for some patients and small centers
are necessary to increase patient access to treatment.
The majority of respondents utilize ECP in patients with
acute/chronic skin GVHD and CTCL, which are assigned
Category II and I indications, respectively in the 2013
ASFA guidelines.7 Interestingly, we confirmed that a small
number of practitioners are also utilizing ECP for several
indications that have not been assigned a category recom-
mendation in the 2013 ASFA guidelines including rejection
following kidney and liver transplant, ulcerative colitis and
other inflammatory bowel disease. Since conducting this
survey, updated ASFA guidelines have been published. The
only notable change to the category recommendations for
ECP shown in Table 2 is the change in non-skin GVHD
from category III to category II.11 Further research into the
efficacy of ECP for conditions that remain uncategorized,
and for which ECP is being performed at some centers, is
warranted.
Although quality control assessment of the ECP product
is not required, the survey revealed that 34% of responding
centers routinely perform quality control testing on the cellu-
lar product prior to re-infusion. The survey was not designed
to assess whether quality control results are utilized in mak-
ing clinical decisions or alterations in the actual procedure.
However, in the setting of a prospective study, the evaluation
of the collected product could potentially be predictive of
response to therapy and overall outcome of patients. Further
evaluation of this topic may contribute to improvement in
understanding of the mechanism of action of ECP.
Current choices for performing ECP are limited to three
options: the Cellex system, the XTS system, or an off-line
system. The majority of centers deliver ECP using one or
both of the approved closed systems while a few centers use
the off-line system. The ease of the integrated system and
reduced risks for infection and infusion errors likely contrib-
ute to the predominant use of closed systems.
The Cellex and the XTS systems offer different features
in relation to the extracorporeal volume, treatment time, and
other parameters, and as a result their use in practice
TABLE 1 Demographics of centers performing ECP
Question N (%)
What is the job classification of staff performing ECP at
your center? (N5130)
Nurses only 109 (84%)
Both nurses and medical technologists 18 (14%)
Medical technologists only 3 (2%)
What is the age range of patients treated with ECP
at your center? (N5130)
Adult Only (>18 years) 67 (52%)
Both Adult and Pediatric 54 (41%)
Pediatric Only (0-18 years) 9 (7%)
Approximately how many patients are treated with ECP
at your center per year? (N5130)
1-20 80 (62%)
21-50 28 (21%)
>50 22 (17%)
Approximately how many ECP procedures do you perform
at your center per year? (N5130)
50-150 45 (35%)
151-300 46 (35%)
301-450 8 (6%)
>450 31 (24%)
Which device(s) are used at your center to perform ECP?
(N5115)
Cellex and XTS 42 (37%)
Cellex ONLY 35 (30%)
XTS ONLY 19 (17%)
XTS and Off-line 8 (7%)
Cellex and Off-line 6 (5%)
Off-line system ONLY 5 (4%)
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demonstrates notable differences. The majority of centers
require a minimum weight limit for patients when using the
XTS. This is in contrast to the use of the Cellex, in which
the majority of centers do not specify a minimum weight
limit. The Cellex system offers the ability to perform dual
needle procedures further decreasing the run time and extra
corporeal volumes when compared to the XTS or even single
needle on the Cellex.12 Due to the discontinuous flow and
extracorporeal volume required while performing ECP pro-
cedures on the XTS system, it can be technically challenging
on smaller weight patients.13
Published reports have demonstrated the safety of the
Cellex in the pediatric patient population, and it has even
been shown to be better tolerated.5,6 In order to accommo-
date lower weight patients, a volume prime or fluid bolus
can be administered. The XTS requires a larger extracorpor-
eal volume potentially warranting a fluid prime to avoid
hypotensive reactions, and when both options are available
the Cellex may preferentially be selected to treat smaller
patients who would be more likely to need a prime in
general.
The majority of responding centers also indicated
that they have laboratory thresholds that would defer the
performance of ECP. XTS users more frequently rely on
laboratory parameters to assess eligibility for ECP. The
most common laboratory parameter reported to impact
the decision to perform ECP was patient pre-procedure
hematocrit, with a threshold in the range of <24–28%
being the most frequent. While not based on ECP-
specific safety data, this is not altogether surprising
given that the extracorporeal volume for these proce-
dures is 220 to 620 ml for the XTS (depending on bowl
size used) and 216–266 ml for the Cellex (double needle
vs. single needle procedure). Intraprocedure hematocrits
in patients have been demonstrated to decrease by up to
9% while on apheresis instruments, and maintenance of
an intraprocedure hematocrit >24% appears to be com-
patible with evidence-based transfusion guidelines for
stable, non-critically ill patients.14,15
There was less consensus surrounding the minimum
platelet count for performance of ECP with a range of pla-
telet count from 20–50,000/mcl that would prevent a
patient from receiving ECP. This again appears to be based
not on ECP-specific safety data but rather on extrapolation
from platelet transfusion thresholds in patients undergoing
interventional procedures or surgeries.16 It is interesting
that the XTS users tend to favor higher platelet counts
even though the Cellex appears to remove more platelets
from peripheral circulation during collection of buffy coat
when compared to the XTS.17
With regard to WBC, almost half of respondents indi-
cated that WBC had to be >1000/ml for either the XTS or
Cellex. Though there is still no data indicating what is an
adequate treatment dose of buffy coat and how that relates to
peripheral WBC count, this reported WBC threshold is a rea-
sonable one based on extrapolations of patient data from
ECP-specific literature regarding collection efficiency
kinetics and clinical outcomes.17,18
TABLE 2 Indications for ECP
In the past 12 months, for which indications has ECP been
performed at your center? (select all that apply) (N5122) N (%) ASFA category*
Graft versus-host disease, Skin (acute/chronic) 108 (89%) II
Cutaneous T-Cell lymphoma 79 (63%) I
Graft versus-host disease, Non-skin (acute/chronic) 77 (63%) III
Solid Organ Transplant Rejection, Lung 53 (43%) II
Solid Organ Transplant Rejection, Heart 26 (21%) II
Scleroderma 9 (7%) III
Nephrogenic Systemic Fibrosis 6 (5%) III
Solid Organ Transplant Rejection, Kidney 5 (4%) NC
Crohn’s Disease 5 (4%) III
Solid Organ Transplant Rejection, Liver 3 (2%) NC
Pemphigus Vulgaris 3 (2%) III
Other Inflammatory Bowel Disease 2 (2%) NC
Ulcerative Colitis 1 (1%) NC
Psoriasis 0 (0%) III
*See reference 7.
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Regardless of instrument used, the most common antico-
agulant used is heparin alone or heparin and/or ACD-A.
There are protocols available to use only ACD-A as the anti-
coagulant during the apheresis, and a few of the reporting
centers use ACD-A exclusively.19 Employing these protocols
can avoid the systemic anticoagulation effects of heparin,
and are necessary when treating patients with contraindica-
tions to heparin.
While no absolute clinical contraindications to perform-
ance of ECP exist (aside from aphakia and idiosyncratic
reactions associated with 8-MOP), the majority of respond-
ing centers indicated that patient clinical status does impact
the decision to perform ECP. In over 90% of respondents,
hemodynamic instability due to sepsis or heart failure would
result in the cancellation of ECP. Patients with positive blood
cultures or fever were additional indications for which ECP
procedures would be cancelled for about half of responding
institutions. Although other types of apheresis procedures
have been shown to be tolerable and feasible in critically ill
adult and pediatric patients, ECP regimens are long-term
therapies performed on an outpatient basis.20–22 Thus, the
performance of ECP under situations of hemodynamic insta-
bility or critical illness, presents an unfavorable risk-benefit
ratio. The fact that these clinical concerns are not universally
shared by all institutions indicates clinical equipoise and the
need for larger studies to clarify appropriate clinical contrain-
dications for performing ECP.
As for any survey-based study, limitations in our study
exist including errors in coverage (i.e., not everyone who
performs ECP received the survey), sampling, non-response,
and measurement (i.e., misinterpretation of questions or pro-
viding different answers for a theoretical survey versus actual
clinical practice). Second, the current study’s findings pri-
marily reflect the practice patterns in North America, specifi-
cally the United States. As such, the patient populations,
ECP instrumentation, and clinical practice patterns cannot
necessarily be generalized to other countries.
Multiple responses may have been received from the
same institution and a hierarchy based on the role of the per-
son completing the survey was used to select the response
used for data analysis. The hierarchy prioritized the Medical
Director which may not have worked equally well for all sur-
vey questions. Further, when results were received from the
same institution they were not compared to ensure that
responses were the same for all survey questions. In addition,
survey data were not weighted based on the number of
patients at each institution. As a result, each responding insti-
tution’s data were counted equally which may skew the data
in favor of practices reported by small volume centers.
This survey was not designed to address differences
between ECP in pediatric versus adult patients. The pediatric
population brings many unique considerations to the per-
formance of ECP, including procedural modifications based
on small body mass/total blood volumes, circuit priming/
fluid boluses, anticoagulation, ability to tolerate extracorpor-
eal procedures, and venous access issues. Future research
TABLE 3 General ECP practices
Question N (%)
What is the typical wait time at your center between
the initial referral and the first ECP procedure? (N5122)
Less than one week 61 (50%)
1-2 weeks 50 (41%)
3 or more weeks 11 (9%)
Which of the following are barriers to patients receiving
ECP treatment at your center? (select all that apply)
(N5122)
Venous access 71 (58%)
Insurance coverage 61 (50%)
Staffing 34 (28%)
Number of devices 30 (25%)
Distance to center 26 (21%)
Which types of venous access are used or considered
acceptable for performing ECP at your center?
(select all that apply) (N5122)
Tunneled catheter 109 (89%)
Peripheral IV 103 (84%)
Vortex/Power port 77 (63%)
High flow PICC 13 (11%)
Do you routinely perform quality control assessment of the
collected ECP product using any laboratory parameters?
(N5122)
Yes 41 (34%)
No 80 (66%)
If you routinely perform quality assessment, which of the
following laboratory parameters on the collected ECP
product are routinely assessed? (select all that apply) (N541)
Total cell count 34 (83%)
Hematocrit 31 (76%)
Lymphocyte count 30 (73%)
Monocyte count 25 (61%)
Bacterial culture 10 (24%)
Flow cytometric assay 5 (12%)
Apoptosis assay 4 (10%)
Evaluation of cell populations 3 (7%)
Proliferation assays 3 7%)
Cytokine levels 1 (2%)
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assessing pediatric ECP will be necessary to obtain meaning-
ful and accurate data on this patient population.
There are several logical future directions that emerge as
a result of this study. The rationales, as well as more details
about relevant clinical algorithms, regarding thresholds of
clinical and laboratory parameters for deferring ECP treat-
ments remain unknown. Based on the institutional heteroge-
neity suggested by the survey results, there is clinical
equipoise in this area that would benefit from future explora-
tions. Regarding characteristics of the ECP buffy coat prod-
uct, future investigations of performing and analyzing
quality control data and relating this back to patient and pro-
cedural variables will assist in identifying what parameters
are significant, and would help support or refute pre-
procedure thresholds that are currently in place. To get a bet-
ter understanding of the volume of procedures being
TABLE 4 Device specific practices
Question XTS Cellex P values
Is there a lower limit for patient weight required for the use of this instrument at your center? (XTS5 69; Cellex5 82)
Yes 41 (60%) 28 (34%) 0.003
No 28 (40%) 54 (66%)
Does your center ever perform volume prime or administer fluid boluses for lower weight patients when using
this instrument? (XTS5 68; Cellex5 80)
Yes 28 (41%) 44 (55%) NS
No 40 (59%) 36 (45%)
Is the decision to provide ECP treatment at your center using this instrument dependent on any patient laboratory
parameters? (XTS5 68; Cellex5 80)
Yes 54 (79%) 50 (63%) 0.03
No 14 (21%) 30 (37%)
Is the decision to perform an individual ECP procedure at your center using this instrument dependent on patient
clinical status? (XTS5 66; Cellex5 76)
Yes 53 (80%) 63 (83%) NS
No 13 (20%) 13 (17%)
Which of the following clinical findings would prevent a patient from receiving ECP treatment at your center using
this instrument? (select all that apply) (XTS5 53; Cellex5 63)
Hemodynamic instability due to active sepsis 50 (94%) 57 (90%)
Hemodynamic instability due to heart failure 41 (77%) 48 (76%)
Positive blood culture in the past 24 h 38 (72%) 38 (60%)
Currently febrile 30 (57%) 37 (59%)
Bleeding risk to due current anticoagulant
or abnormal coagulation testing
28 (53%) 27 (43%)
Bleeding requiring red cell or platelet
transfusion in the past 24 h
22 (42%) 20 (32%)
IV fat emulsion administration in the past 24 h 21 (40%) 22 (35%)
Recent surgery 19 (36%) 16 (25%)
Dialysis or other fluid shifts in the last 24 h 11 (21%) 11 (17%)
Use of ACE-inhibitor in the last 24 h 10 (19%) 11 (17%)
Which anticoagulants are used by your center when performing ECP on this instrument? (XTS5 68; Cellex5 80)
Heparin only 33 (48%) 25 (30%)
ACD-A only 8 (12%) 18 (22%)
Heparin and/or ACD-A 27 (39%) 37 (45%)
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performed for specific disease indications, apheresis data-
bases maintained at the participating institutions could be
combined; in such a way, higher-volume centers performing
ECP for less common indications could be better distin-
guished. Lastly, investigations targeting geographic areas
outside of the United States would help characterize practice
patterns in those areas and provide groups for comparison
studies.
5 | CONCLUSIONS
We report results of a large survey describing current ECP
practice, primarily in North America. Most centers treat
small numbers of patients. Centers are providing ECP for
diseases that are uncategorized in the 2013 ASFA guidelines
based on limited availability of data supporting the use of
ECP for these indications. Although not required, a few cen-
ters are performing quality control testing on the cellular
product prior to re-infusion using a variety of methods. A
limited number of ECP devices are currently available, and
there are device-specific differences in lower weight limits
and laboratory parameters necessary to qualify for ECP.
There is a lack of consensus on clinical factors that may war-
rant deferral of ECP. Further research to support standardiza-
tion of patient qualification, procedure parameters and
product quality assessment is recommended.
SOURCE OF SUPPORT
None.
CONFLICT OF INTEREST
None.
FIGURE 4 Distribution of minimum laboratory test values required for ECP treatment by device. Panel A: The x-axis shows the
minimum required hematocrit versus the y-axis of percent of survey responses reporting this value. Panel B: The x-axis shows the
minimum required platelet count versus the y-axis of percent of survey responses reporting this value. Panel C: The x-axis shows
the minimum requiredWBC count versus the y-axis of percent of survey responses reporting this value
FIGURE 3 Distribution of minimumweight in kilograms
for ECP treatment by device. The x-axis shows the minimum
required weight in kilograms versus the y-axis of percent of
survey responses reporting this value
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